Lavipharm S.A (LAVI) - Total Liabilities

Latest as of December 2024: €72.52 Million EUR ≈ $84.78 Million USD

Based on the latest financial reports, Lavipharm S.A (LAVI) has total liabilities worth €72.52 Million EUR (≈ $84.78 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Lavipharm S.A (LAVI) cash flow conversion to assess how effectively this company generates cash.

Lavipharm S.A - Total Liabilities Trend (2014–2024)

This chart illustrates how Lavipharm S.A's total liabilities have evolved over time, based on quarterly financial data. Check LAVI asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Lavipharm S.A Competitors by Total Liabilities

The table below lists competitors of Lavipharm S.A ranked by their total liabilities.

Company	Country	Total Liabilities
HCM IV Acquisition Corp. Class A Ordinary Share NASDAQ:HACQ	USA	$71.83K
Lionheart Holdings Unit NASDAQ:CUBWU	USA	$10.07 Million
Yongyue Science & Tech Co Ltd SHG:603879	China	CN¥34.49 Million
Tudor Gold Corp V:TUD	Canada	CA$17.37 Million
TYC Brother Industrial Co Ltd TW:1522	Taiwan	NT$28.69 Billion
Valuetronics Holdings Limited F:GJ7	Germany	€756.88 Million
Incap Oyj HE:ICP1V	Finland	€68.95 Million
CompX International Inc NYSE MKT:CIX	USA	$17.56 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Lavipharm S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Lavipharm S.A market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.15	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.37	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.58	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lavipharm S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lavipharm S.A (2014–2024)

The table below shows the annual total liabilities of Lavipharm S.A from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	€72.52 Million ≈ $84.78 Million	+0.70%
2023-12-31	€72.02 Million ≈ $84.19 Million	-2.54%
2022-12-31	€73.89 Million ≈ $86.39 Million	+17.89%
2021-12-31	€62.68 Million ≈ $73.28 Million	-0.42%
2020-12-31	€62.94 Million ≈ $73.58 Million	-1.38%
2019-12-31	€63.82 Million ≈ $74.62 Million	+3.90%
2018-12-31	€61.43 Million ≈ $71.81 Million	-5.10%
2017-12-31	€64.73 Million ≈ $75.67 Million	-19.09%
2016-12-31	€80.00 Million ≈ $93.53 Million	-45.50%
2015-12-31	€146.80 Million ≈ $171.62 Million	+10.55%
2014-12-31	€132.79 Million ≈ $155.24 Million	--

About Lavipharm S.A

AT:LAVI Greece Drug Manufacturers - Specialty & Generic

Market Cap

$327.67 Million

€280.27 Million EUR

Market Cap Rank

#15267 Global

#40 in Greece

Share Price

€1.66

Change (1 day)

+6.69%

52-Week Range

€0.74 - €1.70

All Time High

€2.05